How do different histologic components of mixed endometrial carcinomas affect prognosis? Does it really matter?

Area of Science:

• Gynecologic Oncology
• Pathology
• Clinical Research

Background:

• Endometrial carcinoma presents as pure or mixed subtypes, influencing clinical behavior.
• Understanding the prognostic implications of mixed endometrial carcinomas (MEC) compared to pure types is crucial for patient management.

Purpose of the Study:

• To compare clinicopathological features and survival outcomes of patients with mixed endometrial carcinomas (MEC) against pure endometrioid (EC), serous (SC), and clear cell (CC) carcinomas.
• To evaluate the impact of histologic component percentages on outcomes in MEC.

Main Methods:

• Retrospective review of 302 patients diagnosed with MEC, EC, SC, or CC between 2002 and 2015.
• Analysis of clinicopathological variables, treatment strategies, overall survival (OS), and disease-free (DF) survival.
• Statistical comparison using chi-squared tests and Kaplan-Meier curves.

Main Results:

• Early-stage disease was more common in EC than CC and SC. Adnexal involvement was higher in MEC versus EC (p=0.043).
• Lymphovascular space involvement was more frequent in MEC and CC compared to SC (p=0.001). Omentum involvement was less in EC compared to CC and SC.
• No significant differences in recurrence or OS were observed between MEC and pure subtypes (EC, SC, CC), or based on the proportion of type II component in MEC.

Conclusions:

• Mixed endometrial carcinomas (MEC) exhibit similar survival and recurrence patterns to pure endometrioid, serous, and clear cell subtypes.
• Clinicopathological differences exist between subtypes, but do not translate to distinct survival outcomes in the overall analysis.